Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +15

Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q1 Estimates, But Stock Slips on Margin Headwinds and Manufacturing Glitch - ChartMill

AI-generated analysis

๐Ÿ“ˆ Regeneron Pharmaceuticals reported Q1 non-GAAP EPS of $9.47, beating the analyst consensus estimate of $9.07.

๐Ÿ’ฐ Total revenue reached $3.61 billion, a 19% year-over-year increase that surpassed forecasts of $3.55 billion.

๐Ÿญ GAAP EPS declined to $6.75 from $7.27 due primarily to $0.82 per share in negative impacts from in-process research and development charges.

๐Ÿฉบ Regulatory approvals included FDA clearance for Otarmeni, the first gene therapy for genetic hearing loss, and expanded uses for Dupixent.

โš ๏ธ Gross margins on product sales contracted to 76% from 81% due to a manufacturing disruption at the Limerick, Ireland facility.

๐Ÿ“‰ This manufacturing glitch forced management to revise its full-year 2026 profit outlook downward despite strong underlying product sales.

๐Ÿ’ธ The company resumed production in Q2 but expects gross margins to normalize by the end of that quarter.

๐Ÿ’ฐ Regeneron repurchased $803 million in stock during the quarter and authorized a new $3.0 billion share repurchase program.

๐Ÿ’ต A quarterly cash dividend of $0.94 per share was declared alongside the earnings announcement.

๐Ÿ“‰ Shares declined approximately 1.3% in pre-market trading as investors priced in the risk of sustained margin pressure.

๐Ÿ”ฎ Analysts forecast next quarter revenue of roughly $3.89 billion and non-GAAP EPS of approximately $10.84.

๐Ÿš€ Regeneronโ€™s pipeline includes EYLEA HD and Libtayo, which drove sales but were not enough to fully offset the manufacturing concerns.

Bullish Signals
  • Regeneron Pharmaceuticals reported Q1 non-GAAP earnings per share of $9.47, surpassing the consensus estimate of $9.07 and demonstrating strong profitability.
  • Total revenue for the quarter reached $3.61 billion, representing a 19% year-over-year increase and comfortably beating analyst forecasts.
  • The company secured significant regulatory wins with FDA approval for Otarmeni, the first-ever gene therapy for genetic hearing loss, indicating strong pipeline progress.
  • Expanded approvals for Dupixent in chronic spontaneous urticaria and allergic fungal rhinosinusitis further drive growth from this key product line.
  • Management continues to return value to shareholders through a quarterly cash dividend of $0.94 per share and a new $3.0 billion share repurchase program authorized in April.
  • The company resumed production at its Limerick, Ireland facility in Q2 with gross margins expected to normalize by the end of the second quarter, indicating temporary headwinds will resolve.
  • Analysts expect non-GAAP EPS of roughly $10.84 for the next quarter and full-year 2026 consensus sales over $16 billion, signaling sustained long-term demand.
  • Regeneron maintains strong cash flows as evidenced by its inclusion in High Free Cash Flow Stocks and Quality At A Fair Price screening lists.
Risk Factors
  • Shares slipped in pre-market trading despite beating earnings estimates due to concerns over margin headwinds.
  • A temporary manufacturing disruption at the Limerick, Ireland facility is squeezing gross margins and causing higher inventory write-offs.
  • GAAP gross margin on product sales contracted significantly to 76%, down from 81% a year ago.
  • The company revised its full-year 2026 profit outlook downward as a result of the manufacturing interruption.
  • Even with strong sales growth, the market reacted negatively because revenue beats were not enough to offset the lowered gross margin guidance.
  • Investors are pricing in the risk that margin pressure could continue until the Ireland facility fully ramps back up.
  • GAAP EPS declined year-over-year to $6.75 from $7.27 due to a $0.82 per-share negative impact from IPR&D charges.
Full Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN) reported a strong first quarter that exceeded analyst expectations on both revenue and earnings, driven by robust sales of its newer products and continued collaboration revenue from Dupixent. The company posted non-GAAP earnings per share (EPS) of $9.47 for the quarter ended March 31, 2026, surpassing the consensus estimate of $9.07, while total revenue reached $3.61 billion, a 19% year-over-year increase compared to the forecasted $3.55 billion. GAAP EPS was reported at $6.75, down from $7.27 in the prior year, primarily due to a $0.82 per-share negative impact from in-process research and development (IPR&D) charges. Despite the positive financial results, Regeneron's shares slipped in pre-market trading due to investor concerns regarding margin headwinds and a manufacturing disruption. The gross margin on product sales contracted to 76% from 81% a year ago, largely caused by an interruption in bulk manufacturing at the company's Limerick, Ireland facility that began in Q1. This led to unabsorbed costs and higher inventory write-offs, prompting the company to revise its full-year profit outlook for 2026. The FDA also approved Otarmeni, the first gene therapy for genetic hearing loss, and expanded approvals for Dupixent during the period, marking significant regulatory wins alongside the financial beat. To mitigate shareholder dilution and signal confidence, management executed $803 million in common stock repurchases during the quarter and authorized a new $3.0 billion share repurchase program in April, while also declaring a quarterly cash dividend of $0.94 per share. Management indicated that production resumed in Q2 and expects gross margins to normalize by the end of the second quarter, maintaining solid non-GAAP gross margin guidance between 83% and 84% unchanged R&D and SG&A spending forecasts. For the upcoming quarter, analysts are expecting revenue of approximately $3.89 billion and non-GAAP EPS of roughly $10.84, with the consensus full-year 2026 sales projection standing above $16 billion. The stock's decline suggests that the strong performance from EYLEA HD and Libtayo was insufficient to offset the market's pricing in of continued margin pressure until the Ireland facility fully ramps back up. While the revenue beat validated the company's growth trajectory, the narrowed profitability forecast remains the primary focus for investors as the company navigates the temporary operational challenges at its manufacturing site.